You can buy or sell Xenetic and other stocks, options, ETFs, and crypto commission-free!
Xenetic Biosciences, Inc. engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. Read More It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 13
Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
Company on track to close acquisition of novel XCART platform technology Entry into CAR T space positions company to drive significant momentum over the course of 2019 advancing XCART platform technology XCART initially being developed to target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually 1 FRAMINGHAM, MA / ACCESSWIRE / May 13, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the ...
Yahoo FinanceMay 2
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.
Represents key appointment to bolster scientific and oncology expertise as Company prepares to advance XCART platform technology Internationally renowned expert in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, both with autologous and allogeneic stem cell transplantations Pioneer in developing specific donor-derived immune cells FRAMINGHAM, MA / ACCESSWIRE / May 2, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clini...
-$0.54 per share